Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ADPT Adaptive Biotechnologies Corp
- Stocks
- Healthcare
- NASDAQ: ADPT
Price (delayed)
$9.05
Market cap
$1.37B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.95
Enterprise value
$1.54B
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the
Highlights
ADPT's EPS is up by 36% year-on-year and by 12% since the previous quarter
The company's net income rose by 34% YoY and by 11% QoQ
The quick ratio has declined by 36% year-on-year
ADPT's equity is down by 31% year-on-year and by 6% since the previous quarter
Key stats
What are the main financial stats of ADPT
Market
Valuations
Earnings
Shares outstanding
151.92M
Market cap
$1.37B
Enterprise value
$1.54B
Price to earnings (P/E)
N/A
Price to book (P/B)
7.06
Price to sales (P/S)
7.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.14
Revenue
$189.53M
Gross profit
$118.52M
Operating income
-$143.39M
Net income
-$141.84M
EBIT
-$130.35M
EBITDA
-$106.35M
Free cash flow
-$88.76M
Per share
Balance sheet
Liquidity
EPS
-$0.95
EPS diluted
-$0.95
Free cash flow per share
-$0.59
Book value per share
$1.28
Revenue per share
$1.27
TBVPS
$2.61
Total assets
$510.85M
Total liabilities
$320.63M
Debt
$220.46M
Equity
$190.42M
Working capital
$168.68M
Debt to equity
1.16
Current ratio
2.92
Quick ratio
2.73
Net debt/EBITDA
-1.57
Margins
Efficiency
Dividend
EBITDA margin
-56.1%
Gross margin
62.5%
Net margin
-74.8%
Operating margin
-75.7%
Return on assets
-25.9%
Return on equity
-66.1%
Return on invested capital
-25.7%
Return on capital employed
-30.8%
Return on sales
-68.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADPT stock price
How has the Adaptive Biotechnologies stock price performed over time
Intraday
1.57%
1 week
0.22%
1 month
20.83%
1 year
143.28%
YTD
50.96%
QTD
21.8%
Financial performance
How have Adaptive Biotechnologies's revenue and profit performed over time
Revenue
$189.53M
Gross profit
$118.52M
Operating income
-$143.39M
Net income
-$141.84M
Gross margin
62.5%
Net margin
-74.8%
Adaptive Biotechnologies's operating margin has increased by 40% YoY and by 17% QoQ
ADPT's net margin is up by 39% year-on-year and by 16% since the previous quarter
Adaptive Biotechnologies's operating income has increased by 34% YoY and by 12% QoQ
The company's net income rose by 34% YoY and by 11% QoQ
Price vs fundamentals
How does ADPT's price correlate with its fundamentals
Growth
What is Adaptive Biotechnologies's growth rate over time
Valuation
What is Adaptive Biotechnologies stock price valuation
P/E
N/A
P/B
7.06
P/S
7.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.14
ADPT's EPS is up by 36% year-on-year and by 12% since the previous quarter
ADPT's P/B is 78% above its last 4 quarters average of 3.9 and 42% above its 5-year quarterly average of 4.9
ADPT's equity is down by 31% year-on-year and by 6% since the previous quarter
ADPT's price to sales (P/S) is 68% lower than its 5-year quarterly average of 22.0 but 52% higher than its last 4 quarters average of 4.6
The revenue has grown by 9% YoY and by 6% from the previous quarter
Efficiency
How efficient is Adaptive Biotechnologies business performance
ADPT's return on sales is up by 40% year-on-year and by 17% since the previous quarter
The ROIC has grown by 21% YoY and by 8% from the previous quarter
Adaptive Biotechnologies's ROA has increased by 17% YoY and by 6% from the previous quarter
The ROE has decreased by 3.1% YoY but it has increased by 2.4% QoQ
Dividends
What is ADPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADPT.
Financial health
How did Adaptive Biotechnologies financials performed over time
The total assets is 59% more than the total liabilities
The quick ratio has declined by 36% year-on-year
The current ratio has contracted by 35% YoY
ADPT's debt is 16% greater than its equity
ADPT's debt to equity is up by 40% year-on-year and by 5% since the previous quarter
ADPT's equity is down by 31% year-on-year and by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.